Annals of Surgical Treatment and Research

The Korean Surgical Society (대한외과학회)
권호 표지

Histoculture Drug Response Assay in Colorectal Cancer Specimen

대장암조직을 이용한 항암제 감수성 검사

Kim, Woo-Seok;Lee, Ryung-Ah;Hwang, Dae-Yong;Hong, Young-Joon;Hong, Seok-Il
김우석;이령아;황대용;홍영준;홍석일

  • Published : 20040000
⟨ Previous Next ⟩

Abstract

Purpose: For decades, systemic medical treatment for colorectal cancer has been limited almost entirely to 5- fluorouracil (5-FU). In cases of advanced colorectal cancer, the response rate to standard 5-FU regimen was lower than 20%. Recently, new drugs that have another action mechanism have been introduced-irinotecan, oxaliplatin, raltitrexed, capecitabine, etc. Clinicians have to choose the appropriate drug for advanced cases. Until recently, choice of chemotherapeutic agents was based on the experience of clinicians, or on retrospective or prospective clinical trial reports. In this study, we performed HDRA (histoculture drug response assay) to assess the effectiveness of chemotherapeutic agents in colorectal cancer. Methods: Tumor specimens of 33 colorectal cancers were collected in 15 ml tubes containing PBS buffer. Tissues were minced using an autoclaved knife and histocultured on collagen sponge gel matrix, followed by treatment with 5-FU, 5-FU & leucovorin, oxaliplatin, oxaliplatin & 5-FU, irinotecan, or irinotecan & 5-FU. After 48 hours, cell viability was assessed by MTT assay. The inhibition rate of each drug was calculated for relative survival. Cases of drug responsibility below 30% were regarded as drug resistant cases. Results: Thirty cases were tested. Three cases had synchronous lesion. Thirty-three tissues were evaluated using HDRA. Seventeen cases (53.3%) were rectal cancer. The initial 6 cases were tested using a single agent the other 27 cases were tested using combined agents. The regimen showing the best responses was oxaliplatin with 5-FU (8/26 cases, 30.8%). Seven cases were regarded as chemoresistant cases because they showed low IR below 30% for all agents. Synchronous lesions showed similar drug responses. Conclusion: HDRA is relatively simple and easily applicable to in vitro study to determine the appropriate chemotherapeutic agents. Further study is necessary to assess the effectiveness including tumor recurrence and survival.

Keywords

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA Cancer J Clin 1998;48:6-29. https://doi.org/10.3322/canjclin.48.1.6
  2. Mamounas Eleftherios, Wieand Samuel, Wolmark Norman, Harry DB, James NA, Kyunghee Song. Comparative efficacy of adjuvant chemotherapy in patient with Dukes' B versus Dukes' C colon cancer: result from four National Surgery Adjuvant Breast and bowel Project Adjuvant studies (C-01, C-02, C-03 and C-04). J Clin Oncol 1999;17:1349-55. https://doi.org/10.1200/JCO.1999.17.5.1349
  3. International Multicentre Pooled Analysis of B2 Colon Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356-63. https://doi.org/10.1200/JCO.1999.17.5.1356
  4. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903. https://doi.org/10.1200/JCO.1992.10.6.896
  5. Jody M, Tucker, Celestia Davis, Maria E, Kitcheas, Marlene A, et al. Response to 5-fluorouracil chemotherapy is modified by dietary folic acid deficiency in ApcMin/+ mice. Cancer Letters 2002;187:153-62. https://doi.org/10.1016/S0304-3835(02)00402-0
  6. Ramming KP, Haskell CM. Colorectal malignancies. In Haskell CM (ed) Cancer treatment, 2nd edt. Philadelphia: Saunder; 1985, p.295-334.
  7. M Ducrex, V Boige. Adjuvant chemotherapy for colon cancer. Best practice & Research Clinical Gastroenterology 2002;16:283-298. https://doi.org/10.1053/bega.2002.0287
  8. Alfredo C, Javier G, Eduardo Diaz-Rubio. Oxaliplatin: Results in colorectalcarcinoma, Critical Review in Oncology/Hematology 2002;44:29-44.
  9. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 909-13.
  10. Hoffman RM. In vitro sensitivity assays in cancer: a review, analysis, and progression. J Clin Lab Anal 1991;5:133-43. https://doi.org/10.1002/jcla.1860050211
  11. Hoffman RM. Three-dimensional histoculture: origins and application in cancer reserch. Cancer Cell 1991;3:86-92.
  12. Furukawa T, Kubota T, Watanabe M, Kase S, Takahara T, Yamaguchi H, et al. High in vitro-in vivo correction of drug response using sponge-gel-supported three-dimensional histoculture and the MMT end point. Int J Cancer 1992;52:489-98.
  13. Yang Q, Sakurai T, Yoshimura G, Takashi Y, Suzuma T, Tamaki T, et al. Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C. Anticancer Res 2000;20:4319-22.
  14. Furukawa T, Kubota T, Watanabe M, Kase S, Takahara T, Yamaguchi H, et al. Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and MMT endpoint. Anti-cancer Res 1992;12:1377-82.
  15. Kobayashi H, Higashiyama M, Kodama K, Minamigawa K, Takano T, Yokouchi H, et al. Predictive value of in vitro chemosensitivity test using the 3-dimensional collagen gel droplet culture method in recurrent non-small cell lung cancer. Lung Cancer 2000;29:86.
  16. Bhuvanesh Singh, Rongou Li, Li Xu, Poluri A, Patel S, Shaha AR, et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002;24:437-442. https://doi.org/10.1002/hed.10066
  17. Hirono Y, Ushiyama T, Suzuki K, Fujita K. Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urologic cancer: wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 1999;27:483-8. https://doi.org/10.1007/s002400050139
  18. Kobayashi N, Kubota T, Watanabe M, Otani Y, Teramoto T, Kitajima M. Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively. J Infect Chemother 1999;5:144-8. https://doi.org/10.1007/s101560050024
  19. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP, et al. AJCC cacner staging manual. 5th ed. Philadelphia; Lippincott-Raven; 1997.
  20. Furukawa T, Kubota T, Suto A, Takahara T, Yamaguchi H, Takenchi T. Clinical usefullness of chemosensitivity testing using the MTT assay. J Surg Oncol 1991;48:188-93. https://doi.org/10.1002/jso.2930480310
  21. Tomiak A, Vincent M, Earle CC, Johnston PG, Kocha W, Taylor M, et al. Thymidylate synthase expression in stage II and III colon cancer: a retrospective review. Am J Clin Oncol 2001;24:597-602. https://doi.org/10.1097/00000421-200112000-00014
  22. Schwartz EL, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995;270;19073-7. https://doi.org/10.1074/jbc.270.32.19073
  23. Tanaka-Nozaki M, Onda M, Tanaka N, Kato S. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activi ties and DPD messenger RNA levels. Clin Cancer Res 2001;7:2783-7.
  24. Kabeshima Y, Kubota T, Watanabe M, Sakawa Y, Nishibori H, Hasegawa H, et al. A potential important role for thymidylate synthetase inhibition in antitumor activity of fluoropyrimidine and raltitexed. Anticancer Res 2002;22(6A):3245-52.
  25. Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Pitot H, et al. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol 2001;12:701-7. https://doi.org/10.1023/A:1011182123545
  26. Suda S, Akiyama S, Sekiguchi H, Kasai Y, Ito K, Nakao A. Evaluation of the histoculture drug assay as a sensitivity test for anticancer agents. Surg Today 2002;32:477-81. https://doi.org/10.1007/s005950200080